News & Updates

Show Multimedia Only

EPICS-III shows saroglitazar potential for select PBC patients

08 Jun 2026 by

In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).

EPICS-III shows saroglitazar potential for select PBC patients

08 Jun 2026

People with evidence of HBV at elevated risk of liver-related events

06 Jun 2026

Hepatitis B virus (HBV) low-level viraemia (LLV) may increase the risk of liver-related events, as suggested in a study.

People with evidence of HBV at elevated risk of liver-related events

06 Jun 2026

FOLFIRI-ramucirumab shows promise as second-line therapy in advanced UGI cancers

05 Jun 2026

Combination therapy with FOLFIRI-ramucirumab exhibits survival advantage similar to ramucirumab plus paclitaxel in patients with advanced upper gastrointestinal (UGI) cancers, reveals a study. However, FOLFIRI-ramucirumab is associated with a longer real-world time to treatment discontinuation (rwTTD).

FOLFIRI-ramucirumab shows promise as second-line therapy in advanced UGI cancers

05 Jun 2026

Physical activity intensity matters more for chronic disease prevention

05 Jun 2026 by

Prioritizing physical activity (PA) intensity over volume may yield greater benefits for preventing most noncommunicable diseases (NCDs), a prospective study suggests.

Physical activity intensity matters more for chronic disease prevention

05 Jun 2026

Clipping before ECI lowers risk of ectopic embolisms in gastric varices

04 Jun 2026

Adding clip prior to endoscopic cyanoacrylate injection (ECI) helps prevent ectopic embolism in patients with fundal varices with a portal-systemic shunt, without compromising safety or efficacy, as shown in a recent study.

Clipping before ECI lowers risk of ectopic embolisms in gastric varices

04 Jun 2026

FIB-4 score predicts ESLD onset in healthy adults

03 Jun 2026

The Fibrosis-4 Index (FIB-4) score can be used to predict the risk of end-stage liver disease (ESLD) in young healthy adults, suggests a study.

FIB-4 score predicts ESLD onset in healthy adults

03 Jun 2026

Physical activity, exercise guidelines crucial for people with IBD

30 May 2026

A recent study suggests the need for tailored guidelines for physical activity (PA) or exercise among individuals with inflammatory bowel disease (IBD).

Physical activity, exercise guidelines crucial for people with IBD

30 May 2026

HIV tied to poor outcomes, death in patients with variceal GI bleeding

29 May 2026

HIV-positive patients with variceal upper gastrointestinal bleeding (VUGIB) may experience worse clinical outcomes and poor survival, according to a study.

HIV tied to poor outcomes, death in patients with variceal GI bleeding

29 May 2026

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026 by

Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

25 May 2026

In patients with perianal Crohn’s disease (pCD) treated in routine clinical practice, the use of upadacitinib appears to have a beneficial effect on fistula outcomes, with a more pronounced effect seen for anti-TNF–naïve patients and those with shorter disease duration, according to a multicentre retrospective cohort study.

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

25 May 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

EPICS-III shows saroglitazar potential for select PBC patients

EPICS-III shows saroglitazar potential for select PBC patients

People with evidence of HBV at elevated risk of liver-related events

People with evidence of HBV at elevated risk of liver-related events

FOLFIRI-ramucirumab shows promise as second-line therapy in advanced UGI cancers

FOLFIRI-ramucirumab shows promise as second-line therapy in advanced UGI cancers

Physical activity intensity matters more for chronic disease prevention

Physical activity intensity matters more for chronic disease prevention

Clipping before ECI lowers risk of ectopic embolisms in gastric varices

Clipping before ECI lowers risk of ectopic embolisms in gastric varices

FIB-4 score predicts ESLD onset in healthy adults

FIB-4 score predicts ESLD onset in healthy adults

Physical activity, exercise guidelines crucial for people with IBD

Physical activity, exercise guidelines crucial for people with IBD

HIV tied to poor outcomes, death in patients with variceal GI bleeding

HIV tied to poor outcomes, death in patients with variceal GI bleeding

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

Real-world patients with perianal Crohn’s disease fare well with upadacitinib